Cervical cancer is one of the deadliest cancers among woman all over the world. Mortality from cervical cancer has significantly decreased in developed countries due to widely use of Pap Smear test and HPV DNA and VIA test. VIA test is most adoptable test in developing countries as it is cheaper in comparison to Pap. Samsung, hplc, adriamycin and ibuprofen are some of the major players in the cervical cancer test market.
Cervical cancer is one of the deadliest cancers among woman all over the world. Mortality from cervical cancer has significantly decreased in developed countries due to widely use of Pap Smear test and HPV DNA and VIA test. VIA test is most adoptable test in developing countries as it is cheaper in comparison to Pap. Samsung, hplc, adriamycin and ibuprofen are some of the major players in the cervical cancer test market.
Cervical cancer is one of the deadliest cancers among woman all over the world. Mortality from cervical cancer has significantly decreased in developed countries due to widely use of Pap Smear test and HPV DNA and VIA test. VIA test is most adoptable test in developing countries as it is cheaper in comparison to Pap. Samsung, hplc, adriamycin and ibuprofen are some of the major players in the cervical cancer test market.
Cervical Cancer Test Market & Patients - Pap Smear,
HPV DNA, VIA Test & Patients Worldwide
Renub Research www.renub.com Published: April, 2014 Copyright 2014 Renub Research All Rights Reserved Cervical Cancer Test Market Overview
Cervical cancer is one of the deadliest cancers among woman all over the world. However in the past few decades, mortality from cervical cancer has significantly decreased in developed countries due to widely use of Pap smear test. HPV DNA and VIA test are other popular tests used across world. VIA test is most adoptable test in developing countries as it is cheaper in comparison to Pap smear test and HPV DNA test.
Cervical cancer test market is dominated by United States in 2013. Germany and United Kingdom are other top two leaders in this market place. In Asian region, China and India are top two countries having largest cervical cancer test population. Few countries have also shown a decline in cervical cancer test market. However VIA test market accounts for largest share in cervical cancer test market in the case of developing countries like India and China.
A high prevalence of HPV-infected patients across the globe, rising incidences of teenage sexual cases, a rising number of organized cervical cancer programs initiated by governments and NGOs and introduction of low cost VIA test are some of the major growth drivers for the cervical cancer test market. However, lack of insufficient healthcare infrastructure and lack of cervical cancer screening awareness are the major hinder for cervical testing market.
Renub Research report titled "Cervical Cancer Test Market & Patients - Pap Smear, HPV DNA, VIA Test & Patients Worldwide provides a comprehensive analysis of the current state of this market and likely future evolution over the next 5 years. This 232 page report with 240 Figures and 14 Table provides a complete analysis of top 20 Countries Cervical Cancer Test Market & Population. All the 20 countries in the report have been studied from 3 viewpoints.
1. Cervical cancer Test Population (2007-2020) Pap smear test population (2007-2020) HPV DNA test population (2007-2020) VIA test Population (2007-2020)
2. Cervical Cancer Mortality Population (2001-2011)
3. Cervical Cancer Test Market (2007-2020) Pap smear test market (2007-2020) HPV DNA test market (2007-2020) VIA test market (2007-2020)
All the 20 Countries studied in the report are as follows
1. United Kingdom 2. France 3. Germany 4. Italy 5. Spain 6. Sweden 7. Switzerland 8. Norway 9. Netherlands 10. United States 11. Canada 12. Japan 13. Korea 14. Singapore 15. Malaysia 16. Australia 17. India 18. China 19. Thailand 20. Indonesia Renub Research Page 4 of 24
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts. Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non- printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.
Renub Research Page 5 of 24 About Us
R Re en nu ub b R Re es se ea ar rc ch h is a leading Market Research and Information Analysis Company with centers at Noida India and Roswell USA. We have long-term experience especially in international Business-to-Business Researches, Surveys, Business and Consulting. Throughout the years we have acquired expertise in most market sectors, including Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others.
Our core team is comprised of an experienced people holding graduate, post graduate and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science and many more. Our research help make the business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis and forecasting that is essential in todays ultra-competitive markets.
For more information on us or to view any of our sample work you can mail us at info@renub.com
Renub Research Page 6 of 24
Published By R Re en nu ub b R Re es se ea ar rc ch h 1 st Floor, C-86, Sector10 Noida 201301 Phone: +91-120-421-9822, 254-5750 (India) +1-678-302-0700 (USA) Fax : +91-120-424-9780 Email: info@renub.com www.renub.com
Cervical Cancer Test Market & Patients - Pap Smear, HPV DNA, VIA Test & Patients Worldwide Renub Research, 2014 Edition 1.0 All rights reserved. This publication is protected by copyright. No part of it may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic mechanical, photocopying, recording or otherwise without the prior written permission of the publishers
Renub Research Page 7 of 24 Table of Contents
1. Executive Summary 2. Worldwide Cervical Cancer Test (Screening) Population & Forecast 3. Worldwide Cervical Cancer Test (Screening) Market & Forecast 3.1 Worldwide Cervical Cancer Pap Smear Test (Screening) Market & Forecast 3.2 Worldwide Cervical Cancer HPV DNA Test (Screening) Market & Forecast 3.3 Worldwide - Cervical Cancer Visual Inspection with Acetic Acid (VIA) Test (Screening) Market & Forecast 4. Worldwide Cervical Cancer Test (Screening) Population Share, Market Share & Forecast 4.1 Worldwide Cervical Cancer Test (Screening) Population Share & Forecast 4.2 Worldwide Cervical Cancer Test (Screening) Market Share & Forecast 4.3 Worldwide Cervical Cancer Pap Smear Test (Screening) Market Share & Forecast 4.4 Worldwide Cervical Cancer HPV DNA Test (Screening) Market Share & Forecast 4.5 Worldwide Cervical Cancer VIA Test (Screening) Market Share & Forecast 5. United Kingdom Cervical Cancer Test Analysis 5.1 United Kingdom Cervical Cancer Test (Screening) Population 5.1.1 United Kingdom Cervical Cancer Pap Smear Test Population & Forecast 5.1.2 United Kingdom Cervical Cancer HPV DNA Test Population & Forecast 5.2 United Kingdom Cervical Cancer Mortality 5.3 United Kingdom Cervical Cancer Test (Screening) Analysis 5.3.1 United Kingdom Cervical Cancer Test Market & Forecast 5.3.2 United Kingdom Pap Smear Test Market & Forecast 5.3.3 United Kingdom HPV DNA Test Market & Forecast 6. France Cervical Cancer Test Analysis 6.1 France Cervical Cancer Test (Screening) Population 6.1.1 France Cervical Cancer Pap Smear Test Population & Forecast 6.1.2 France Cervical Cancer HPV DNA Test Population & Forecast 6.2 France Cervical Cancer Mortality 6.3 France Cervical Cancer Test (Screening) Analysis Renub Research Page 8 of 24 6.3.1 France Cervical Cancer Test Market & Forecast 6.3.2 France Pap Smear Test Market & Forecast 6.3.3 France HPV DNA Test Market & Forecast 7. Germany Cervical Cancer Test Analysis 7.1 Germany Cervical Cancer Test (Screening) Population 7.1.1 Germany Cervical Cancer Pap Smear Test Population & Forecast 7.1.2 Germany Cervical Cancer HPV DNA Test Population & Forecast 7.2 Germany Cervical Cancer Mortality 7.3 Germany Cervical Cancer Test (Screening) Market 7.3.1 Germany Cervical Cancer Test Market & Forecast 7.3.2 Germany Pap Smear Test Market & Forecast 7.3.3 Germany HPV DNA Test Market & Forecast 8. Italy Cervical Cancer Test Analysis 8.1 Italy Cervical Cancer Test (Screening) Population 8.1.1 Italy Cervical Cancer Pap Smear Test Population & Forecast 8.1.2 Italy Cervical Cancer HPV DNA Test Population & Forecast 8.2 Italy Cervical Cancer Mortality 8.3 Italy Cervical Cancer Test (Screening) Market 8.3.1 Italy Cervical Cancer Test Market & Forecast 8.3.2 Italy Pap Smear Test Market & Forecast 8.3.3 Italy HPV DNA Test Market & Forecast 9. Spain Cervical Cancer Test Analysis 9.1 Spain Cervical Cancer Test (Screening) Population 9.1.1 Spain Cervical Cancer Pap Smear Test Population & Forecast 9.1.2 Spain Cervical Cancer HPV DNA Test Population & Forecast 9.2 Spain Cervical Cancer Mortality 9.3 Spain Cervical Cancer Test (Screening) Market 9.3.1 Spain Cervical Cancer Test Market & Forecast 9.3.2 Spain Pap Smear Test Market & Forecast 9.3.3 Spain HPV DNA Test Market & Forecast 10. Sweden Cervical Cancer Test Analysis 10.1 Sweden Cervical Cancer Test (Screening) Population 10.1.1 Sweden Cervical Cancer Pap Smear Test Population & Forecast Renub Research Page 9 of 24 10.1.2 Sweden Cervical Cancer HPV DNA Test Population & Forecast 10.2 Sweden Cervical Cancer Mortality 10.3 Sweden Cervical Cancer Test (Screening) Market 10.3.1 Sweden Cervical Cancer Test Market & Forecast 10.3.2 Sweden Pap Smear Test Market & Forecast 10.3.3 Sweden HPV DNA Test Market & Forecast 11. Switzerland Cervical Cancer Test Analysis 11.1 Switzerland Cervical Cancer Test (Screening) Population 11.1.1 Switzerland Cervical Cancer Pap Smear Test Population & Forecast 11.1.2 Switzerland Cervical Cancer HPV DNA Test Population & Forecast 11.2 Switzerland Cervical Cancer Mortality 11.3 Switzerland Cervical Cancer Test (Screening) Market 11.3.1 Switzerland Cervical Cancer Test Market & Forecast 11.3.2 Switzerland Pap smear Test Market & Forecast 11.3.3 Switzerland HPV DNA Test Market & Forecast 12. Norway Cervical Cancer Test Analysis 12.1 Norway Cervical Cancer Test (Screening) Population 12.1.1 Norway Cervical Cancer Pap Smear Test Population & Forecast 12.1.2 Norway Cervical Cancer HPV DNA Test Population & Forecast 12.2 Norway Cervical Cancer Mortality 12.3 Norway Cervical Cancer Test (Screening) Market 12.3.1 Norway Cervical Cancer Test Market & Forecast 12.3.2 Norway Pap Smear Test Market & Forecast 12.3.3 Norway HPV DNA Test Market & Forecast 13. Netherlands Cervical Cancer Test Analysis 13.1 Netherlands Cervical Cancer Test (Screening) Population 13.1.1 Netherlands Cervical Cancer Pap Smear Test Population & Forecast 13.1.2 Netherlands Cervical Cancer HPV DNA Test Population & Forecast 13.2 Netherlands Cervical Cancer Mortality 13.3 Netherlands Cervical Cancer Test (Screening) Market 13.3.1 Netherlands Cervical Cancer Test Market & Forecast 13.3.2 Netherlands Pap Smear Test Market & Forecast 13.3.3 Netherlands HPV DNA Test Market & Forecast Renub Research Page 10 of 24 14. United States Cervical Cancer Test Analysis 14.1 United States Cervical Cancer Test (Screening) Population 14.1.1 United States Cervical Cancer Pap Smear Test Population & Forecast 14.1.2 United States Cervical Cancer HPV DNA Test Population & Forecast 14.2 United States Cervical Cancer Mortality 14.3 United States Cervical Cancer Test (Screening) Market 14.3.1 United States Cervical Cancer Test Market & Forecast 14.3.2 United States Pap smear Test Market & Forecast 14.3.3 United States HPV DNA Test Market & Forecast 15. Canada Cervical Cancer Test Analysis 15.1 Canada Cervical Cancer Test (Screening) Population 15.1.1 Canada Cervical Cancer Pap Smear Test Population & Forecast 15.1.2 Canada Cervical Cancer HPV DNA Test Population & Forecast 15.2 Canada Cervical Cancer Mortality 15.3 Canada Cervical Cancer Test (Screening) Market 15.3.1 Canada Cervical Cancer Test Market & Forecast 15.3.2 Canada Pap Smear Test Market & Forecast 15.3.3 Canada HPV DNA Test Market & Forecast 16. Japan Cervical Cancer Test Analysis 16.1 Japan Cervical Cancer Test (Screening) Population 16.1.1 Japan Cervical Cancer Pap Smear Test Population & Forecast 16.1.2 Japan Cervical Cancer HPV DNA Test Population & Forecast 16.2 Japan Cervical Cancer Mortality 16.3 Japan Cervical Cancer Test (Screening) Market 16.3.1 Japan Cervical Cancer Test Market & Forecast 16.3.2 Japan Pap Smear Test Market & Forecast 16.3.3 Japan HPV DNA Test Market & Forecast 17. South Korea Cervical Cancer Tests Analysis 17.1 South Korea - Cervical Cancer Test (Screening) Population 17.1.1 South Korea - Cervical Cancer Pap Smear Test Population & Forecast 17.1.2 Korea Cervical Cancer HPV DNA Test Population & Forecast 17.2 Korea Cervical Cancer Mortality Renub Research Page 11 of 24 17.3 Korea Cervical Cancer Test (Screening) Market 17.3.1 Korea Cervical Cancer Test Market & Forecast 17.3.2 Korea Pap Smear Test Market & Forecast 17.3.3 Korea HPV DNA Test Market & Forecast 18. Singapore Cervical Cancer Tests Analysis 18.1 Singapore - Cervical Cancer Test (Screening) Population 18.1.1 Singapore - Cervical Cancer Pap Smear Test Population & Forecast 18.1.2 Singapore Cervical Cancer HPV DNA Test Population & Forecast 18.2 Singapore Cervical Cancer Test (Screening) Market 18.2.1 Singapore Cervical Cancer Test Market & Forecast 18.2.2 Singapore Pap Smear Test Market & Forecast 18.2.3 Singapore HPV DNA Test Market & Forecast 19. Malaysia Cervical Cancer Test Analysis 19.1 Malaysia - Cervical Cancer Test (Screening) Population 19.1.1 Malaysia Cervical Cancer Pap Smear Test Population & Forecast 19.1.2 Malaysia Cervical Cancer HPV DNA Test Population & Forecast 19.2 Malaysia Cervical Cancer Test (Screening) Market 19.2.1 Malaysia Cervical Cancer Test Market & Forecast 19.2.2 Malaysia Pap Smear Test Market & Forecast 19.2.3 Malaysia HPV DNA Test Market & Forecast 20. Australia Cervical Cancer Test Analysis 20.1 Australia - Cervical Cancer Test (Screening) Population 20.1.1 Australia Cervical Cancer Pap Smear Test Population & Forecast 20.1.2 Australia Cervical Cancer HPV DNA Test Population & Forecast 20.2 Australia Cervical Cancer Mortality 20.3 Australia Cervical Cancer Test (Screening) Market 20.3.1 Australia Cervical Cancer Test Market & Forecast 20.3.2 Australia Pap Smear Test Market & Forecast 20.3.3 Australia HPV DNA Test Market & Forecast 21. India Cervical Cancer Test Analysis 21.1 India - Cervical Cancer Test (Screening) Population 21.1.1 India Cervical Cancer Pap Smear Test Population & Forecast 21.1.2 India Cervical Cancer HPV DNA Test Population & Forecast Renub Research Page 12 of 24 21.1.3 India Cervical Cancer VIA Test Population & Forecast 21.2 India Cervical Cancer Test (Screening) Market 21.2.1 India Cervical Cancer Test Market & Forecast 21.2.2 India Pap Smear Test Market & Forecast 21.2.3 India HPV DNA Test Market & Forecast 21.2.4 India VIA Test Market & Forecast 22. China Cervical Cancer Test Analysis 22.1 China - Cervical Cancer Test (Screening) Population 22.1.1 China Cervical Cancer Pap smear Test Population & Forecast 22.1.2 China Cervical Cancer HPV DNA Test Population & Forecast 22.1.3 China Cervical Cancer VIA Test Population & Forecast 22.2 China - Cervical Cancer Test (Screening) Market 22.2.1 China Cervical Cancer Test Market & Forecast 22.2.2 China Pap Smear Test Market & Forecast 22.2.3 China HPV DNA Test Market & Forecast 22.2.4 China VIA Test Market & Forecast 23. Thailand Cervical Cancer Test Analysis 23.1 Thailand - Cervical Cancer Test (Screening) Population 23.1.1 Thailand Cervical Cancer Pap Smear Test Population & Forecast 23.1.2 Thailand Cervical Cancer VIA Test Population & Forecast 23.2 Thailand Cervical Cancer Test (Screening) Market 23.2.1 Thailand Cervical Cancer Test Market & Forecast 23.2.2 Thailand Pap smear Test Market & Forecast 23.2.3 Thailand VIA Test Market & Forecast 24. Indonesia Cervical Cancer Test Analysis 24.1 Indonesia Cervical Cancer Test (Screening) Population 24.1.1 Indonesia Cervical Cancer Pap Smear Test Population & Forecast 24.1.2 Indonesia Cervical Cancer HPV DNA Test Population & Forecast 24.1.3 Indonesia Cervical Cancer VIA Test Population & Forecast 24.1.4 Indonesia Cervical Cancer Both (Pap Smear & VIA) Test Population & Forecast 24.2 Indonesia Cervical Cancer Test (Screening) Market 24.2.1 Indonesia Cervical Cancer Test Market & Forecast 24.2.2 Indonesia Pap smear Test Market & Forecast 24.2.3 Indonesia HPV DNA Test Market & Forecast Renub Research Page 13 of 24 24.2.4 Indonesia VIA Test Market & Forecast 24.2.5 Indonesia Cervical Cancer Both (Pap Smear & VIA) Test Market & Forecast 25. Cervical Cancer Test Market Growth Drivers 25.1 Point No. 1 25.2 Point No. 2 25.3 Point No. 3 26. Challenges in Cervical Cancer Test Market 26.1 Point No. 1 26.2 Point No. 2
Renub Research Page 14 of 24 List of Figures:
Figure 2-1: Worldwide Cervical Cancer Test Population (Million), 2005 2013 Figure 2-2: Worldwide Forecast for Cervical Cancer Test Population (Million), 2014 2020 Figure 3-1: Worldwide Cervical Cancer Test Market (Million US$), 2005 2013 Figure 3-2: Worldwide Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 3-3: Worldwide Cervical Cancer Pap Smear Test Market (Million US$), 2005 2013 Figure 3-4: Worldwide Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2014 2020 Figure 3-5: Worldwide Cervical Cancer HPV DNA Test Market (Million US$), 2005 2013 Figure 3-6: Worldwide Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2014 2020 Figure 3-7: Worldwide Cervical Cancer VIA Test Market (Million US$), 2005 2013 Figure 3-8: Worldwide Forecast for Cervical Cancer VIA Test Market (Million US$), 2014 2020 Figure 5-1: United Kingdom Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 5-2: United Kingdom Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 5-3: United Kingdom Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 5-4: United Kingdom Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 5-5: United Kingdom Cervical Cancer Mortality (Number), 2001 2011 Figure 5-6: United Kingdom Cervical Cancer Test Market (Million US$), 2005 2013 Figure 5-7: United Kingdom Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 5-8: United Kingdom Pap Smear Test Market (Million US$), 2005 2013 Figure 5-9: United Kingdom Forecast for Pap Smear Test Market (Million US$), 2014 2020 Figure 5-10: United Kingdom HPV DNA Test Market (Million US$), 2005 2013 Figure 5-11: United Kingdom Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 6-1: France Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 6-2: France Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 6-3: France Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 6-4: France Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 6-5: France Cervical Cancer Mortality (Number), 2001 2011 Figure 6-6: France Cervical Cancer Test Market (Million US$), 2005 2013 Figure 6-7: France Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 6-8: France Pap Smear Test Market (Million US$), 2005 2013 Figure 6-9: France Forecast for Pap Smear Test Market (Million US$), 2014 2020 Figure 6-10: France HPV DNA Test Market (Million US$), 2005 2013 Figure 6-11: France Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 7-1: Germany Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Renub Research Page 15 of 24 Figure 7-2: Germany Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 7-3: Germany Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 7-4: Germany Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 7-5: Germany Cervical Cancer Mortality (Number), 2001 2011 Figure 7-6: Germany Cervical Cancer Test Market (Million US$), 2005 2013 Figure 7-7: Germany Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 7-8: Germany Pap Smear Test Market (Million US$), 2005 2013 Figure 7-9: Germany Forecast for Pap Smear Test Market (Million US$), 2014 2020 Figure 7-10: Germany HPV DNA Test Market (Million US$), 2005 2013 Figure 7-11: Germany Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 8-1: Italy Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 8-2: Italy Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 8-3: Italy Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 8-4: Italy Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 8-5: Italy Cervical Cancer Mortality (Number), 2001 2011 Figure 8-6: Italy Cervical Cancer Test Market (Million US$), 2005 2013 Figure 8-7: Italy Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 8-8: Italy Pap Smear Test Market (Million US$), 2005 2013 Figure 8-9: Italy Forecast for Pap Smear Test Market (Million US$), 2014 2020 Figure 8-10: Italy HPV DNA Test Market (Million US$), 2005 2013 Figure 8-11: Italy Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 9-1: Spain Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 9-2: Spain Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 9-3: Spain Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 9-4: Spain Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 9-5: Spain Cervical Cancer Mortality (Number), 2001 2011 Figure 9-6: Spain Cervical Cancer Test Market (Million US$), 2005 2013 Figure 9-7: Spain Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 9-8: Spain Pap Smear Test Market (Million US$), 2005 2013 Figure 9-9: Spain Forecast for Pap Smear Test Market (Million US$), 2014 2020 Figure 9-10: Spain HPV DNA Test Market (Million US$), 2005 2013 Figure 9-11: Spain Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 10-1: Sweden Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 10-2: Sweden Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 10-3: Sweden Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 10-4: Sweden Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 10-5: Sweden Cervical Cancer Mortality (Number), 2001 2011 Renub Research Page 16 of 24 Figure 10-6: Sweden Cervical Cancer Test Market (Million US$), 2005 2013 Figure 10-7: Sweden Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 10-8: Sweden Pap Smear Test Market (Million US$), 2005 2013 Figure 10-9: Sweden Forecast for Pap Smear Test Market (Million US$), 2014 2020 Figure 10-10: Sweden HPV DNA Test Market (Million US$), 2005 2013 Figure 10-11: Sweden Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 11-1: Switzerland Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 11-2: Switzerland Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 11-3: Switzerland Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 11-4: Switzerland Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 11-5: Switzerland Cervical Cancer Mortality (Number), 2001 2011 Figure 11-6: Switzerland Cervical Cancer Test Market (Million US$), 2005 2013 Figure 11-7: Switzerland Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 11-8: Switzerland Pap Smear Test Market (Million US$), 2005 2013 Figure 11-9: Switzerland Forecast for Pap Smear Test Market (Million US$), 2014 2020 Figure 11-10: Switzerland HPV DNA Test Market (Million US$), 2005 2013 Figure 11-11: Switzerland Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 12-1: Norway Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 12-2: Norway Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 12-3: Norway Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 12-4: Norway Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 12-5: Norway Cervical Cancer Mortality (Number), 2001 2011 Figure 12-6: Norway Cervical Cancer Test Market (Million US$), 2005 2013 Figure 12-7: Norway Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 12-8: Norway Pap Smear Test Market (Million US$), 2005 2013 Figure 12-9: Norway Forecast for Pap Smear Test Market (Million US$), 2014 2020 Figure 12-10: Norway HPV DNA Test Market (Million US$), 2005 2013 Figure 12-11: Norway Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 13-1: Netherlands Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 13-2: Netherlands Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 13-3: Netherlands Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 13-4: Netherlands Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 13-5: Netherlands Cervical Cancer Mortality (Number), 2001 2011 Renub Research Page 17 of 24 Figure 13-6: Netherlands Cervical Cancer Test Market (Million US$), 2005 2013 Figure 13-7: Netherlands Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 13-8: Netherlands Pap Smear Test Market (Million US$), 2005 2013 Figure 13-9: Netherlands Forecast for Pap Smear Test Market (Million US$), 2014 2020 Figure 13-10: Netherlands HPV DNA Test Market (Million US$), 2005 2013 Figure 13-11: Netherlands Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 14-1: United States Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 14-2: United States Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 14-3: United States Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 14-4: United States Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 14-5: United States Cervical Cancer Mortality (Number), 2001 2011 Figure 14-6: United States Cervical Cancer Test Market (Million US$), 2005 2013 Figure 14-7: United States Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 14-8: United States Pap smear Test Market (Million US$), 2005 2013 Figure 14-9: United States Forecast for Pap Smear Test Market (Million US$), 2014 2020 Figure 14-10: United States HPV DNA Test Market (Million US$), 2005 2013 Figure 14-11: United States Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 15-1: Canada Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 15-2: Canada Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 15-3: Canada Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 15-4: Canada Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 15-5: Canada Cervical Cancer Mortality (Number), 2001 2011 Figure 15-6: Canada Cervical Cancer Test Market (Million US$), 2005 2013 Figure 15-7: Canada Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 15-8: Canada Pap Smear Test Market (Million US$), 2005 2013 Figure 15-9: Canada Forecast for Pap Smear Test Market (Million US$), 2014 2020 Figure 15-10: Canada HPV DNA Test Market (Million US$), 2005 2013 Figure 15-11: Canada Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 16-1: Japan Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 16-2: Japan Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 16-3: Japan Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 16-4: Japan Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 16-5: Japan Cervical Cancer Mortality (Number), 2001 2011 Figure 16-6: Japan Cervical Cancer Test Market (Million US$), 2005 2013 Figure 16-7: Japan Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Renub Research Page 18 of 24 Figure 16-8: Japan Pap Smear Test Market (Million US$), 2005 2013 Figure 16-9: Japan Forecast for Pap Smear Test Market (Million US$), 2014 2020 Figure 16-10: Japan HPV DNA Test Market (Million US$), 2005 2013 Figure 16-11: Japan Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 17-1: Korea Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 17-2: Korea Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 17-3: Korea Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 17-4: Korea Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 17-5: Korea Cervical Cancer Mortality (Number), 2001 2011 Figure 17-6: Korea Cervical Cancer Test Market (Million US$), 2005 2013 Figure 17-7: Korea Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 17-8: Korea Pap Smear Test Market (Million US$), 2005 2013 Figure 17-9: Korea Forecast for Pap Smear Test Market (Million US$), 2014 2020 Figure 17-10: Korea HPV DNA Test Market (Million US$), 2005 2013 Figure 17-11: Korea Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 18-1: Singapore Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 18-2: Singapore Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 18-3: Singapore Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 18-4: Singapore Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 18-5: Singapore Cervical Cancer Test Market (Million US$), 2005 2013 Figure 18-6: Singapore Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 18-7: Singapore Pap Smear Test Market (Million US$), 2005 2013 Figure 18-8: Singapore Forecast for Pap Smear Test Market (Million US$), 2014 2020 Figure 18-9: Singapore HPV DNA Test Market (Million US$), 2005 2013 Figure 18-10: Singapore Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 19-1: Malaysia Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 19-2: Malaysia Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 19-3: Malaysia Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 19-4: Malaysia Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 19-5: Malaysia Cervical Cancer Test Market (Million US$), 2005 2013 Figure 19-6: Malaysia Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 19-7: Malaysia Pap smear Test Market (Million US$), 2005 2013 Figure 19-8: Malaysia Forecast for Pap smear Test Market (Million US$), 2014 2020 Figure 19-9: Malaysia HPV DNA Test Market (Million US$), 2005 2013 Renub Research Page 19 of 24 Figure 19-10: Malaysia Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 20-1: Australia Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 20-2: Australia Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 20-3: Australia Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 20-4: Australia Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 20-5: Australia Cervical Cancer Mortality (Number), 2001 2011 Figure 20-6: Australia Cervical Cancer Test Market (Million US$), 2005 2013 Figure 20-7: Australia Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 20-8: Australia Pap Smear Test Market (Million US$), 2005 2013 Figure 20-9: Australia Forecast for Pap Smear Test Market (Million US$), 2014 2020 Figure 20-10: Australia HPV DNA Test Market (Million US$), 2005 2013 Figure 20-11: Australia Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 21-1: India Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 21-2: India Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 21-3: India Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 21-4: India Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 21-5: India Cervical Cancer VIA Test Population (Thousand), 2005 2013 Figure 21-6: India Forecast for Cervical Cancer VIA Test Population (Thousand), 2014 2020 Figure 21-7: India Cervical Cancer Test Market (Million US$), 2005 2013 Figure 21-8: India Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 21-9: India Pap smear Test Market (Million US$), 2005 2013 Figure 21-10: India Forecast for Pap smear Test Market (Million US$), 2014 2020 Figure 21-11: India HPV DNA Test Market (Million US$), 2005 2013 Figure 21-12: India Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 21-13: India VIA Test Market (Million US$), 2005 2013 Figure 21-14: India Forecast for VIA Test Market (Million US$), 2014 2020 Figure 22-1: China Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 22-2: China Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 22-3: China Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 22-4: China Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 22-5: China Cervical Cancer VIA Test Population (Thousand), 2005 2013 Figure 22-6: China Forecast for Cervical Cancer VIA Test Population (Thousand), 2014 2020 Figure 22-7: China Cervical Cancer Test Market (Million US$), 2005 2013 Figure 22-8: China Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 22-9: China Pap smear Test Market (Million US$), 2005 2013 Figure 22-10: China Forecast for Pap Smear Test Market (Million US$), 2014 2020 Renub Research Page 20 of 24 Figure 22-11: China HPV DNA Test Market (Million US$), 2005 2013 Figure 22-12: China Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 22-13: China VIA Test Market (Million US$), 2005 2013 Figure 22-14: China Forecast for VIA Test Market (Million US$), 2014 2020 Figure 23-1: Thailand Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 23-2: Thailand Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 23-3: Thailand Cervical Cancer VIA Test Population (Thousand), 2005 2013 Figure 23-4: Thailand Forecast for Cervical Cancer VIA Test Population (Thousand), 2014 2020 Figure 23-5: Thailand Cervical Cancer Test Market (Million US$), 2005 2013 Figure 23-6: Thailand Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 23-7: Thailand Pap smear Test Market (Million US$), 2005 2013 Figure 23-8: Thailand Forecast for Pap Smear Test Market (Million US$), 2014 2020 Figure 23-9: Thailand VIA Test Market (Million US$), 2005 2013 Figure 23-10: Thailand Forecast for VIA Test Market (Million US$), 2014 2020 Figure 24-1: Indonesia Cervical Cancer Pap Smear Test Population (Thousand), 2005 2013 Figure 24-2: Indonesia Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 2020 Figure 24-3: Indonesia Cervical Cancer HPV DNA Test Population (Thousand), 2005 2013 Figure 24-4: Indonesia Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 2020 Figure 24-5: Indonesia Cervical Cancer VIA Test Population (Thousand), 2005 2013 Figure 24-6: Indonesia Forecast for Cervical Cancer VIA Test Population (Thousand), 2014 2020 Figure 24-7: Indonesia Cervical Cancer Both (Pap Smear & VIA) Test Population (Thousand), 2005 2013 Figure 24-8: Indonesia Forecast for Cervical Cancer Both (Pap Smear & VIA) Test Population (Thousand), 2014 2020 Figure 24-9: Indonesia Cervical Cancer Test Market (Million US$), 2005 2013 Figure 24-10: Indonesia Forecast for Cervical Cancer Test Market (Million US$), 2014 2020 Figure 24-11: Indonesia Pap Smear Test Market (Million US$), 2005 2013 Figure 24-12: Indonesia Forecast for Pap Smear Test Market (Million US$), 2014 2020 Figure 24-13: Indonesia HPV DNA Test Market (Million US$), 2005 2013 Figure 24-14: Indonesia Forecast for HPV DNA Test Market (Million US$), 2014 2020 Figure 24-15: Indonesia VIA Test Market (Million US$), 2005 2013 Figure 24-16: Indonesia Forecast for VIA Test Market (Million US$), 2014 2020 Figure 24-17: Indonesia Both (Pap smear & VIA) Test Market (Million US$), 2005 2013 Figure 24-18: Indonesia Forecast for Both (Pap Smear & VIA) Test Market (Million US$), 2014 2020
Renub Research Page 21 of 24 List of Tables:
Table 4-1: Worldwide Cervical Cancer Test Population Share (Percent), 2005 2013 Table 4-2: Worldwide Forecast for Cervical Cancer Test Population Share (Percent), 2014 2020 Table 4-3: Worldwide Cervical Cancer Test Market Share (Percent), 2005 2013 Table 4-4: Worldwide Forecast for Cervical Cancer Test Market Share (Percent), 2014 2020 Table 4-5: Worldwide Cervical Cancer Pap Smear Test Market Share (Percent), 2005 2013 Table 4-6: Worldwide Forecast for Cervical Cancer Pap Smear Test Market Share (Percent), 2014 2020 Table 4-7: Worldwide Cervical Cancer HPV DNA Test Market Share (Percent), 2005 2013 Table 4-8: Worldwide Forecast for Cervical Cancer HPV DNA Test Market Share (Percent), 2014 2020 Table 4-9: Worldwide Cervical Cancer VIA Test Market Share (Percent), 2005 2013 Table 4-10: Worldwide Forecast for Cervical Cancer VIA Test Market Share (Percent), 2014 2020 Table 25-1: Worldwide List of Countries which offer VIA Test via National Programs, 2010 Table 25-2: Worldwide List of Countries which offer VIA Test via Pilot Programs, 2010 Table 25-3: Worldwide Prevalence (Percent) of Young Women (1544 Years) who Have Sex before the Age of 15 Years, 1994 2006 Table 25-4: Worldwide HPV Prevalence (Percent) among Women with Normal Cervical Cytology, 2010
Renub Research Page 22 of 24 Order Form
Scan and e-mail this page to info@renub.com, alternatively one can also write the Contact Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780
Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to info@renub.com
Format
Report Title: Cervical Cancer Test Market & Patients - Pap Smear, HPV DNA, VIA Test & Patients Worldwide
Single User (Email from Publisher) Hard Copy (Mail Delivery) CD Rom (Mail Delivery) Global Site License (Multiple User License) US$ 1,490 US$ 1,790 US$ 1,590 US$ 2,300
For ordering this report: Three easy ways to place your order:
1) Order online by Credit Card (Visa, MasterCard, etc.): http://www.renub.com/report/cervical-cancer-test-market-patients---pap-smear-hpv-dna-via- --test-patients---worldwide-131
2) Order by Wire Transfer: http://www.renub.com/report/wiretransfer.aspx?id=131&pid=1521
To pay by Wire Transfer, please, fill in your contact details in the form below:
Renub Research Page 23 of 24 Bank Details
Account Name: Renub Research A/C No.: 109102000023296 Name of Bank: IDBI Bank Ltd. Swift Code: IBKLINBB010 Bank Address: 4 th Floor Indian Red Cross Building 1 Red Cross Road Opposite Parliament Street New Delhi 110001 India
Contact Information
First Name: Last Name: Email: Job Title: Company: Address: City: Postal/Zip Code: Country: Phone: Mobile: Fax: Report Format: Your message:
Renub Research Page 24 of 24 3) Order by Check
Please post the check accompanied by this form, to:
Company Address: Renub Research 1 st Floor C-86, Sector -10 Noida - 201301 Uttar Pradesh India Phone: +91-120-421-9822, 424-9780
For free Sample copy report or to view any of our sample work please contact us at info@renub.com or call +91-120-421-9822 (India), +1-678-302-0700 (USA)